<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1470">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339426</url>
  </required_header>
  <id_info>
    <org_study_id>HRI-COVID-19-Anti-Malarial-001</org_study_id>
    <nct_id>NCT04339426</nct_id>
  </id_info>
  <brief_title>Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection</brief_title>
  <official_title>Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HonorHealth Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HonorHealth Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate anti-malarial/anti-infective single-agent and in combination for&#xD;
      patients with confirmed COVID-19 infection. The first combination to be evaluated is&#xD;
      atovaquone and azithromycin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized study to evaluate anti-malarial/anti-infective&#xD;
      single-agents and combination therapies for patients with confirmed COVID-19 infection&#xD;
      requiring therapy as determined by risk factors for complication (age, comorbid illness) or&#xD;
      the presence of respiratory compromise. The first combination to be evaluated is&#xD;
      atovaquone/azithromycin. Other combinations may be added to the study at future amendments as&#xD;
      information of potential benefit arises. The first part of the study will enroll 25 evaluable&#xD;
      male and female patients 18 years of age or older with confirmed COVID-19 infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virology Cure Rate</measure>
    <time_frame>10 days</time_frame>
    <description>COVID-19 serology testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of GI adverse events</measure>
    <time_frame>47 days</time_frame>
    <description>Measure incidence of diarrhea, vomiting, nausea and constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Toxicity</measure>
    <time_frame>10 days</time_frame>
    <description>12-Lead ECG daily if QTc &gt;500 msec</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in WBC w Diff, B cells, T cells, NK cells</measure>
    <time_frame>10 days</time_frame>
    <description>Measure blood counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in cytokine levels, IL-1, IL-6, IL-12, IL-18, TNF-a</measure>
    <time_frame>10 days</time_frame>
    <description>Measure changes in plasma cytokines throughout course of infection</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Atovaquone/Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone/Azithromycin</intervention_name>
    <description>Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)</description>
    <arm_group_label>Atovaquone/Azithromycin</arm_group_label>
    <other_name>Mepron/Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female patients age 18 years or older&#xD;
&#xD;
          -  COVID-19 confirmed positive test results&#xD;
&#xD;
          -  High risk for complications including with Medium (5-6) or High (More than or equal to&#xD;
             7) NEWS score&#xD;
&#xD;
          -  Hematology criteria: ANC &gt;500 cells/mcl, HGB &gt;9 g/dl, Platelet count &gt;75,000/mcl&#xD;
&#xD;
          -  Metabolic criteria: Serum creatinine &lt;2.0 mg/dl or calculated creatinine clearance&#xD;
             (using Cockcroft-Gault) &gt;30 ml/min, AST/ALT &lt;5x ULN AND Total Bilirubin WNL (for&#xD;
             patients with Gilbert's disease, direct bilirubin &lt;ULN)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COVID-19 negative test result&#xD;
&#xD;
          -  Inability to adhere to study protocol requirements&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Other acute or chronic medical or psychiatric condition that in the judgment of the&#xD;
             investigator would make the participant inappropriate to take part in the study&#xD;
&#xD;
          -  Pregnant and breastfeeding individuals&#xD;
&#xD;
          -  QTc interval greater than 470 msecs at baseline&#xD;
&#xD;
          -  History of hypersensitivity to atovaquone and/or azithromycin.&#xD;
&#xD;
          -  History of known intolerance to atovaquone and/or azithromycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HonorHealth Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Lewandowski, RN</last_name>
    <phone>480-583-0760</phone>
    <email>klewandowski@honorhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Lane</last_name>
    <phone>480-323-1081</phone>
    <email>hlane@honorhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lewandowski, RN</last_name>
      <phone>480-583-0760</phone>
      <email>klewandowski@honorhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Lane</last_name>
      <phone>480-323-1081</phone>
      <email>hlane@honorhealth.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

